• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
78,918.79 425.25
( 0.54%)
Global Indices
Nasdaq
49,467.44 867.71
(1.79%)
Dow Jones
7,146.92 84.64
(1.20%)
Hang Seng
58,818.22 342.32
(0.59%)
Nikkei 225
10,660.47 70.48
(0.67%)
Forex
USD-INR
93.19 -0.12
(-0.13%)
EUR-INR
109.85 -0.18
(-0.16%)
GBP-INR
126.25 -0.31
(-0.25%)
JPY-INR
0.59 0.00
(-0.15%)

EQUITY - MARKET SCREENER

Mahindra & Mahindra Ltd
Industry :  Automobiles - Passenger Cars
BSE Code
ISIN Demat
Book Value()
500520
INE101A01026
534.8629059
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
M&M
25.89
397848.4
EPS(TTM)
Face Value()
Div & Yield %
123.56
5
0.76
 

arup india pvt ltd
Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.